Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
16.71
Oct 29 • 3:59 PM ET Dollar change+0.21 Percentage change(1.27%)
Aftermarket Close
16.29
Aftermarket • 7:52 PM ET Dollar change-0.42 Percentage change(-2.52%)
Index
-
Market Cap
415.08M
Enterprise Value
452.42M
Income
-43.08M
Sales
75.63M
Book/sh
-0.90
Cash/sh
0.45
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
226
IPO
Mar 29, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
5.49
P/B
-
P/C
37.26
P/FCF
-
EV/EBITDA
-
EV/Sales
5.98
Quick Ratio
0.34
Current Ratio
0.41
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.44
EPS next Y
-0.38
EPS next Q
-0.24
EPS this Y
45.66%
EPS next Y
59.31%
EPS next 5Y
-
EPS past 3/5Y
-17.81% 3.38%
Sales past 3/5Y
27.66% 38.09%
EPS Y/Y TTM
26.76%
Sales Y/Y TTM
1.00%
EPS Q/Q
33.76%
Sales Q/Q
17.83%
Insider Own
1.93%
Insider Trans
11.44%
Inst Own
20.05%
Inst Trans
-2.60%
ROA
-81.36%
ROE
-1746.27%
ROIC
-
Gross Margin
81.56%
Oper. Margin
-46.57%
Profit Margin
-56.96%
SMA20
18.32%
SMA50
38.14%
SMA200
157.41%
Trades
Shs Outstand
30.93M
Shs Float
24.36M
52W High
16.68 0.18%
52W Low
3.22 418.94%
Volatility
6.06% 6.14%
ATR (14)
0.81
RSI (14)
80.38
Beta
2.10
Rel Volume
0.66
Avg Volume
473.31K
Volume
312,849
Perf Week
8.37%
Perf Month
42.46%
Perf Quarter
279.77%
Perf Half Y
286.81%
Perf YTD
384.35%
Perf Year
352.85%
Perf 3Y
79.87%
Perf 5Y
1.46%
Perf 10Y
66.27%
Prev Close
16.50
Price
16.71
Change %
1.27%
Consensus
Buy
Avg. Price Target
$12.99
Implied Upside
-22.3%
Analysts8incl. previous ratings
Rating Distribution8 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 07, 2026Upgrade
BBTIG Research
Neutral → Buy$7-58.1%
May 15, 2026Upgrade
LLake Street
Hold → Buy$6-64.1%
Mar 05, 2026Initiated
NNorthland Capital
Outperform$10-40.2%
Nov 20, 2025Upgrade
BBTIG Research
Sell → Neutral
Aug 08, 2025Downgrade
BBTIG Research
Neutral → Sell$3-82.0%
Dec 24, 2024Initiated
DD. Boral Capital
Buy$25+49.6%
Apr 11, 2024Downgrade
BBTIG Research
Buy → Neutral
Jun 27, 2023Initiated
CCantor Fitzgerald
Overweight$23+37.6%
Mar 02, 2021Initiated
PPiper Sandler
Overweight$27+61.6%
Aug 27, 2020Initiated
BAC logoBBofA Securities
Buy$42+151.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woody Joseph FralinDirectorJun 09 '26Buy4.005,20020,800107,961Jun 10 09:17 PM
Woody Joseph FralinDirectorJun 09 '26Buy4.1910,00041,900102,761Jun 09 04:58 PM
Woody Joseph FralinDirectorJun 03 '26Buy4.0910,00040,94992,761Jun 05 05:00 PM
Woody Joseph FralinDirectorJun 01 '26Buy4.3010,00043,00010,000Jun 03 04:30 PM
Woody Joseph FralinDirectorJun 02 '26Buy4.1910,00041,93620,000Jun 03 04:30 PM
O'Toole David DCFOMay 20 '26Buy4.262,0008,520145,927May 20 04:30 PM
O'Toole David DCFOMay 19 '26Buy4.242,0008,480143,927May 19 04:30 PM
O'Toole David DCFOFeb 19 '26Buy4.153,00012,450140,127Feb 23 04:30 PM
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
PresidentMr. Cary G. Vance
Chief Financial OfficerMr. David O'Toole
Chief Legal & Compliance Officer & Corporate SecretaryMs. Nicole Linda Kelsey
P.M.P.Dr. Niraj Doshi J.D.
Senior Vice President of Scientific & Medical AffairsDr. Katie Bush Ph.D.